Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Ischl – page 18

307 clinical trials in Bad Ischl, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Ischl at a glance
307
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

307 trials in Bad Ischl

Open in trial search

Uveitis+1

Not recruiting

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Encephalopathy neonatal+1

Not recruiting

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Allopurinol Sodium
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Prostate cancer

Not recruiting

Study on Enzalutamide and Drug Combination for High-Risk Localized Prostate Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Cancer Trials Ireland

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Ischl

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focused on Chronic Obstructive Pulmonary Disease (COPD) treatment optimization through combination therapy approaches. Studies explore the effectiveness of triple therapy combinations including bronchodilators and anti-inflammatory medications.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Treatment Optimization

Clinical investigations aim to improve patient outcomes in moderate to severe COPD cases.

02 Pulmonary Therapeutics

Advanced research examining the efficacy of benralizumab in treating patients with moderate to very severe COPD. Focus on reducing exacerbation frequency in patients with elevated blood eosinophils.

  • Exacerbation Management
  • Targeted Therapy
  • Disease Control

Studies specifically target patients with a history of frequent COPD exacerbations.

03 Respiratory Care Innovation

Development of new therapeutic approaches using metered-dose inhalers for COPD management. Research combines multiple active ingredients to achieve optimal bronchodilation and anti-inflammatory effects.

  • Medication Delivery Systems
  • Combination Therapies
  • Treatment Efficacy

Emphasis on improving delivery methods and treatment effectiveness for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.